Garbuzov reported an eight-fold increase in the production of pharmaceutical substances by the Moscow plant

In 2026, Sputnik Technopolis, a resident of the Technopolis Moscow SEZ, increased the production of pharmaceutical substances 8 times compared to 2025. Details were announced by the Minister of the Government of Moscow, head of the Department of Investment and Industrial Policy Anatoly Garbuzov.

More than 100 pharmaceutical enterprises work in the capital, employing about 17,000 people. With the support of the city, the companies are modernizing their capacities and increasing the production of modern domestic drugs. Thus, the Moscow plant in 2026 increased the production of pharmaceutical substances eight times, said Garbuzov.

Rituximab is produced in a full cycle - from the substance to packaging. This year, the production of cetuximab, the first biosimilar in Russia for the treatment of head and neck cancer, was launched. The company has a research center for the development of original and import-substituting medicines.

The plant produces drugs for the treatment of oncological and autoimmune diseases, most of them are included in the list of vital and essential medicines. The products are used in medical institutions in Moscow and other regions.

General Director of the plant Alexander Shishov said that the company is increasing capacity to provide patients with advanced drugs, develops a full cycle of production of popular drugs in Russia and, thanks to the support of Moscow, modernizes production and expands the product line.